Navigation Links
Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Date:8/20/2007

PALATINE, IL, Aug. 20 /PRNewswire-FirstCall/ -- Acura Pharmaceuticals, Inc. (OTC Bulletin Board: ACUR) (the "Company") today announced it has entered into a Securities Purchase Agreement (the "Agreement"), with an investor group comprised of Vivo Ventures Fund VI L.P., Vivo Ventures Fund VI Affiliates Fund, L.P., GCE Holdings LLC and certain individual investors (the "Investors"). Pursuant to the Agreement, the Investors purchased 23,605,551 Units ("Units") at a price of $1.08 per Unit with each Unit consisting of four shares of the Company's common stock, $0.01 par value, and a warrant to purchase one share of common stock. 13,842,590 of the Units were purchased for cash, with the balance of 9,962,961 Units issued in consideration for the conversion of all of the Company's $10.544 million in outstanding bridge loan indebtedness. Net cash proceeds to the Company, after expenses relating to closing the transaction, are estimated to be approximately $14.5 million.

As a condition to the Agreement, the Company's 2004 Note in the principal amount of $5.0 million was amended to, among other things, extend the maturity date to December 31, 2008 from September 30, 2007 and to set the interest rate at 10% from the prior rate of prime rate plus 4.5% (currently 12.75%). A more detailed description of this equity financing may be reviewed in the Company's Form 8-K filed with the Securities and Exchange Commission.

Use of Proceeds

The Company will utilize a portion of the net proceeds from the transaction described above to fund Study 105, the pivotal phase 3 trial for OxyADF (oxycodone HCl and niacin) Tablets, its lead product candidate utilizing Aversion(R) Technology. Study 105 is a randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of the safety and efficacy of OxyADF Tablets for the treatment of acute, moderate to severe postoperative pain following bunionectomy surgery in adult patients. This is a 3-arm clinical trial comp
'/>"/>

SOURCE Acura Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
5. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
6. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
9. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... has announced the addition of the "Investigation ... report to their offering. Developed by ... of Novolog) is an important drug for the ... aspart, as a fast- acting insulin analog, starts ...
(Date:8/28/2015)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; ... MYL ) shareholder vote regarding its planned unsolicited ... Mylan,s offer to Perrigo shareholders have always been, and ... reflection of the value available to Perrigo shareholders, and ... has allowed its shareholders to consider," said Joseph ...
(Date:8/28/2015)... -- The report "Eubiotics Market by Type (Probiotics, Prebiotics, Organic ... & by Region ( North America , ... Rest of the World) - Global Trends and Forecast to ... valued at USD 4.62 Billion in 2014 and is projected ... of 7.4% from 2015 to 2020. Browse ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
... Alcoa (NYSE: AA ) today announced a ... CDXS ) and CO2 Solution Inc. (TSX-V: CST), focused ... neutralizing the material to create a commercially viable product. ... world,s leading aluminum producer and will be funded by Alcoa ...
... a new market research report is available in its catalogue: ... http://www.reportlinker.com/p0470752/World-In-Vitro-Diagnostics-Market.html Global ... The Freedonia Group projects world demand for in vitro diagnostic ... in 2014. Based on the advanced nature of medical delivery ...
Cached Medicine Technology:Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products 2Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products 3Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products 4Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products 5Reportlinker Adds World In Vitro Diagnostics Market 2Reportlinker Adds World In Vitro Diagnostics Market 3Reportlinker Adds World In Vitro Diagnostics Market 4Reportlinker Adds World In Vitro Diagnostics Market 5Reportlinker Adds World In Vitro Diagnostics Market 6Reportlinker Adds World In Vitro Diagnostics Market 7Reportlinker Adds World In Vitro Diagnostics Market 8Reportlinker Adds World In Vitro Diagnostics Market 9
(Date:8/28/2015)... ... August 28, 2015 , ... ... Addictions specialist, Dr. James Strawbridge, gives a new approach on solutions in his ... begin with the employer and employees getting together for meaningful group meetings. "This ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... loyalty at a low cost. Personalized with practice contact information and logos, Calendars ... Dental offices can also incorporate Calendars into seasonal mailings, thank you and welcome ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... for those seeking to go deep sea diving. The act of recreational ... decompression sickness; for these reasons, it is vital that all recreational and professional ...
(Date:8/28/2015)... ... August 28, 2015 , ... Popular review ... millionaire dating sites . According to the listings, MillionaireMatch.com bags ... this category. , A spokesperson of Top5MillionaireDatingSites.com said, “This website has ...
(Date:8/28/2015)... ... ... Inc. magazine today ranked PREVENT Life Safety No. 3660 on its ... The list was unveiled online at Inc.com and is the most competitive crop in ... ranks higher on the list than any other company in their industry. , PREVENT ...
Breaking Medicine News(10 mins):Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Top5MillionaireDatingSites.com Publishes Its First List of Reviews of the Best Millionaire Dating Sites 2Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2
... generic drugs will get them into consumers, hands quicker, but ... marketing researcher has found. A mathematical model created by ... the chances of getting there first and commanding the best ... Ching is an associate professor of marketing at the University ...
... By Kathleen Doheny HealthDay Reporter , MONDAY, Feb. ... levels of exposure to a substance found in a commonly ... a mental developmental test at 3 years of age than ... at all, new research says. Megan Horton, a postdoctoral ...
... , PHILADELPHIA - So-called barrier sites -- the skin, ... allergens, pollutants, viruses, bacteria, and parasites. Understanding how the ... for understanding such inflammatory diseases as asthma, psoriasis, IBD, ... body,s barriers. David Artis, PhD, professor of ...
... , MONDAY, Feb. 7 (HealthDay News) -- The ... along with the economy, statistics released Monday suggest. ... performed in the country, up five percent from 2009, ... nearly 1.6 million cosmetic surgical procedures and 11.6 cosmetic ...
... PICK: Profiling malaria-causing parasites The majority of ... parasite Plasmodium falciparum . Most at risk are young ... led by Patrick Duffy, at the National Institutes of Health, ... falciparum parasites in such a way that they are ...
... gambling rates continue to rise, University of Missouri researchers ... as an effective and inexpensive way for people with ... Matthew Martens, associate professor of Educational, School and ... his team of researchers received a $172,500 grant ...
Cached Medicine News:Health News:Prenatal Exposure to Pesticides May Harm Kids' Development 2Health News:As Economy Picks Up, So Do Number of Nips & Tucks 2Health News:JCI online early table of contents: Feb. 7, 2011 2Health News:JCI online early table of contents: Feb. 7, 2011 3Health News:JCI online early table of contents: Feb. 7, 2011 4Health News:JCI online early table of contents: Feb. 7, 2011 5Health News:JCI online early table of contents: Feb. 7, 2011 6Health News:JCI online early table of contents: Feb. 7, 2011 7Health News:Simple feedback could be effective therapy for addictive behaviors 2
Caspar Curette, 250 mm, 10"....
Bone Curette, 160 mm...
Bone Currettes...
Townsend is a endocervical stainless-steel curette with round tapered tip....
Medicine Products: